Abstracts tagged "Lupus nephritis"

Abstract Number: 1283 • ACR Convergence 2025
Impact of Guideline Concordant Care of Renal Outcomes in Childhood-Onset Lupus Nephritis
Alisha Akinsete¹, Orysya Soroka², Mangala Rajan², Karen Onel³, Monika Safford² and Iris Navarro-Millan⁴, ¹Weill Cornell Medical Center, New York, NY, ²Weill Cornell Medicine, New York, ³HSS, New York, NY, ⁴Weill Cornell Medicine, Hospital for Special Surgery, Poughkeepsie, NY
Background/Purpose: End-stage renal disease (ESRD) is a serious complication of lupus nephritis (LN), yet the effect of guideline-concordant care on this outcome is unclear. Despite…
Abstract Number: 0663 • ACR Convergence 2025
iPSC-Derived Off-the-Shelf anti-CD19 CAR T cells Deliver Improved Clinical Outcomes in Lupus with Reduced or No Conditioning Chemotherapy
Parastoo Fazeli¹, Jennifer Medlin², Andrew BitMansour³, Debra Zack⁴, Rebecca Elstrom⁵, Bertha Villa⁵, Lilly Wong⁶, John Goulding⁷, Nicholas Brookhouser⁵, Trever Greene⁵, Cara Bickers⁵, Carol Wong⁵, Beatrice Ferguson⁵, Tom Lee⁵, Jode Goodridge⁵, Marie Hu⁸, Veronika Bachanova⁸, Jeffrey Miller⁹, Bahram Valamehr⁶, Matthew Lunning¹⁰ and Vaneet Sandhu⁵, ¹UMN, ST PAUL, MN, ²University of Nebraska Medical Center, Omaha, NE, ³Fate Therapeutics, Inc., San Carlos, CA, ⁴Fate Therapeutics, Inc., Solana Beach, CA, ⁵Fate Therapeutics, Inc., San Diego, ⁶Fate Therapeutics, Inc., San Diego, CA, ⁷Fate Therapeutics, San Diego, ⁸University of Minnesota, Minneapolis, ⁹University of Minnesota, Minneaspolis, MN, ¹⁰University of Nebraska, Omaha
Background/Purpose: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy shows promise in autoimmune disease. However, autologous CAR T-cell therapy is limited by prolonged pre- and…
Abstract Number: 0611 • ACR Convergence 2025
Venous Thromboembolism in Patients with Lupus Nephritis: Frequency and Risk Factors – A Cohort Study
Fadi Kharouf¹, Pankti Mehta², Qixuan Li², Dafna D. Gladman³, Laura Whitall Garcia⁴ and Zahi Touma⁵, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada
Background/Purpose: Venous thromboembolism (VTE) is a known complication of systemic lupus erythematosus (SLE), yet there is a lack of high-quality studies specifically focused on lupus…
Abstract Number: 1258 • ACR Convergence 2025
Upadacitinib in the treatment of Rheumatoid Arthritis – Interstitial Lung Disease. National multicenter study of 25 patients in clinical practice.
Ana Serrano-Combarro¹, Belén Atienza-mateo², Leticia del Olmo Perez³, Sara García-Perez⁴, Guillermo Gonzalez Mozo de Rosales⁵, Jose Rosas Gómez de Salazar⁶, ana Urruticoechea-Arana⁷, Andrea García-Valle⁸, Jesús Loarce⁹, Paula García-Escudero¹⁰, Bryan Josué Flores Robles¹¹, Rafael B. Melero-González¹², Alicia Garcia¹³, Maria Martín López¹⁴, Patricia López Viejo¹⁵, Maria Jose Perez Gaan¹⁶, Nuria Vegas Revenga¹⁷, Angel Garcia-Aparicio¹⁸, M.Pilar Bernabeu Gonzalvez¹⁹, Juan Moreno Morales²⁰ and Ricardo Blanco²¹, ¹Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Inmunopathology group, Santander, Santander, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, PALMA DE MALLORCA/BALEARES, Spain, ³HGU Nuestra Señora del Prado, Talavera de la Reina, Talavera de la Reina, Spain, ⁴Complejo Hospitalario de Vigo, Vigo, Spain, ⁵Basurto University Hospital, Bilbao, Spain, ⁶Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ⁷Rheumatology Division. Hospital Universitario Son Espases, Palma de Mallorca, Spain, ⁸Rheumatology. Hospital General Río Carrión, Palencia, Castilla y Leon, Spain, ⁹Ramón y Cajal University Hospital, Madrid, Spain, ¹⁰Hospital Universitario Álava, Bilbao, Spain, ¹¹Hospital San Pedro, Logroño, Spain, ¹²COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, ¹³Rheumatologist, La Laguna, Spain, ¹⁴Hospital ¹² de Octubre, Madrid, Spain, ¹⁵Hospital Severo Ochoa (Leganés), Leganes, Spain, ¹⁶Hospital Universitario Virgen de las Nieves, Granada, Spain, ¹⁷Galdakao- Usansolo University Hospital, Galdakao, Spain, ¹⁸Hospital Universitario de Toledo, Toledo, Spain, ¹⁹Rheumatology Department, Dr. Balmis General University Hospital, Alicante, Spain., Alicante, Spain, ²⁰Hospital Universitario Santa Lucia Cartagena, Cartagena, Spain, ²¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain

Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept and rituximab are usually the recommended drugs. JAK inhibitors (JAKi)…
Abstract Number: 1853 • ACR Convergence 2025
SAP Expression in SLE T Cells is Associated with Differentiation Towards Pro-Inflammatory Effector Subsets.
Yevgeniya Gartshteyn¹, Daniel Portnoy², Matthieu Paiola³, Anca Askanase² and Adam Mor⁴, ¹Columbia University Medical Center, Glen Rock, NJ, ²Columbia University Medical Center, New York, NY, ³Columbia University Irving Medical Center, New York, NY, ⁴Columbia University, New York, NY
Background/Purpose: SAP is an adaptor protein that mediates signaling downstream of SLAMF T cell receptors. SAP deficiency results in X-linked Lymphoproliferative immunodeficiency characterized by impaired…
Abstract Number: 1540 • ACR Convergence 2025
Association of Hypoalbuminemia with Serious Infections in Systemic Lupus Erythematosus Patients Receiving Dialysis
Ping Hsuan Kuo¹, Pu Jun Fang², Chien-Chih Lai³ and Yi-Syuan Sun⁴, ¹Taipei Veteran General Hospital, Taipei City, Taiwan (Republic of China), ²Tri-Service General Hospital, Hukou Township, Taiwan (Republic of China), ³Taipei Veterans General Hospital, Taipei City, Taiwan (Republic of China), ⁴taipei VGHTPE, ???, Taiwan (Republic of China)
Background/Purpose: Lupus nephritis, a key manifestation of systemic lupus erythematosus (SLE), can progress to end-stage kidney disease and increase patient burden. While patients with SLE…
Abstract Number: 1282 • ACR Convergence 2025
Real-world use of belimumab in childhood-onset SLE in Spain: cross-sectional analysis from a multicenter study (JULES registry)
Alina-Lucica Boteanu¹, Clara Udaondo², Joan Calzada³, Daniel Clemente Garulo⁴, Juan Carlos Nieto Gonzáles⁵, Eugenia Enriquez⁶, inmaculada Calvo Penades⁷, Lourdes Villalobos⁸, Belen Sevilla⁹, Sara Murias¹⁰, Berta Magallares¹¹, Ana Capilla¹², Jaime Arroyo¹³, Beatriz Bravo¹⁴, Gisela Diez-Cordoves¹⁵, Marisol Camacho¹⁶, Genaro grana¹⁷, Juan Jose Bethencourt¹⁸, Pablo Mesa¹⁹, Natalia Palmou²⁰, Mireia Lopez Corbeto²¹, Judith Sanchez²², Maria Isabel Gonzalez²³, isabel Patora Granados bautista²⁴, Clara Moriano²⁵, Diego Dios¹⁷, Lorena Exposito²⁶, Alicia Garcia²⁷, Laura Martin²⁸, David Fernandez²⁹, Laura Trujillo¹⁴, Anahy Maria Brandy³⁰ and CARLOS GUILLEN-ASTETE³¹, ¹H.U. Ramón y Cajal, Madrid, Spain, ²La Paz University Hospital, Madrid, Spain, ³University Hospital Sant Joan de Deu, Barcelona, Spain, ⁴H.U Niño Jesús, Madrid, Spain, ⁵H.U Gregorio Marañón, Madrid, Spain, ⁶Clínica Universidad de Navarra, Madrid, Spain, ⁷Pediatric Rheumatology Department. HUP La Fe, Valencia, Spain, ⁸Ramon y Cajal Hospital, MADRID, Spain, ⁹Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, ¹⁰H.U Central de Asturias, Oviedo, Spain, ¹¹Hospital de Sant Pau, Bareclona, ¹²H.U de La Merced, Sevilla, Spain, ¹³HOSPITAL UNIVERSITARIO LA PAZ, MADRID, ¹⁴H.U Virgen de Las Nieves, Granada, Spain, ¹⁵H. R. U. Malaga, Malaga, Spain, ¹⁶H.U. Virgen del Rocío, Sevilla, Spain, ¹⁷H.U de A Coruña, A Coruña, Spain, ¹⁸H.U. Canarias, Canarias, Spain, ¹⁹H.U Virgen de la Arrixaca, Murcia, Spain, ²⁰H.U. marques de Valdecilla, Santander, Spain, ²¹H.U Vall d´Hebron, Barcelona, Spain, ²²Pediatric Rheumatology Department, Taulí Hospital Universitari-Institut d'Investigació i Innovació Parc Taulí (I³PT-CERCA), Sabadell (Spain)., Sabadell, Spain, ²³H.U. La Fé, Valencia, Spain, ²⁴H.U Toledo, Toledo, Spain, ²⁵Hospital León, LEON, Castilla y Leon, Spain, ²⁶H.U Canarias, Canarias, Spain, ²⁷Rheumatologist, La Laguna, Spain, ²⁸H.R.U Malaga, Malaga, Spain, ²⁹Complejo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ³⁰Hospital Germans Trias i Pujol, Badalona, Spain, ³¹H.U Ramón y Cajal, Madrid, Spain
Background/Purpose: SLE is a multisystemic autoimmune disease with several manifestations. Childhood-onset SLE (cSLE) has a more severe disease course than adult-onset SLE, with a higher…
Abstract Number: 0661 • ACR Convergence 2025
Real-world Effectiveness and Usage of Voclosporin: Data from the Enlight-LN Registry
Leanna Wise¹, Laura Geraldino-Pardilla², Niloofar Nobakht³, Mohammad Kamgar³, Amber Rosales⁴, Barbara McIntosh⁴ and Ron Flauto⁴, ¹LAGMC/Keck Medicine of USC, Los Angeles, ²Columbia University, New York, NY, ³University of California Los Angeles, Los Angeles, CA, ⁴Aurinia Pharmaceuticals Inc., Edmonton, AB, Canada
Background/Purpose: The 2024 American College of Rheumatology Lupus Nephritis (LN) Guideline recommends triple immunosuppressive therapy, including the option of a calcineurin inhibitor (CNI)-based regimen, for…
Abstract Number: 0601 • ACR Convergence 2025
Precipitants and Long-Term Outcomes of Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus: A Multicenter Cohort Study and Systematic Review
Ali Ardekani¹, Alain Sanchez-Rodriguez², Mariana González-Treviño³, Jose Meade-Aguilar⁴, Maria O. Valenzuela-Almada⁵, Hannah Langenfeld¹, Larry J. Prokop⁴, Isabel Valenzuela Almada⁶, Gabriel Figueroa-Parra⁷, Nicolás Sánchez Domínguez⁸, Alejandro A. Rabinstein⁴, M. Hassan Murad⁴, Cynthia Crowson⁹ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²ABC Medical Center, Ciudad de México, Federal District, Mexico, ³Vanderbilt University Medical Center, Nashville, ⁴Mayo Clinic, Rochester, ⁵Children’s National Medical Center, Washington D.C, ⁶Universidad Panamericana, Ciudad de México, Federal District, Mexico, ⁷Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ⁸Clínica Alemana de Santiago, Santiago, Chile, ⁹Mayo Clinic, Stewartvillle, MN
Background/Purpose: Posterior reversible encephalopathy syndrome (PRES) is an underrecognized neuroradiologic complication of SLE, characterized by acute neurological symptoms and vasogenic edema on neuroimaging. Its precipitating…
Abstract Number: 2458 • ACR Convergence 2025
Obecabtagene autoleucel (obe-cel), a CD19-targeting Autologous Chimeric Antigen Receptor T-cell Therapy (CAR T) with a fast off-rate binding domain, in Patients (pts) with Severe, Refractory Systemic Lupus Erythematosus (srSLE): Preliminary Results from the Phase I CARLYSLE Study
Maria Leandro¹, Ruth Pepper², Ben Parker³, Eleni Tholouli⁴, David Jayne⁵, Ben Uttenthal⁶, Josefina Cortés-Hernández⁷, Pere Barba⁷, José Andrés Román Ivorra⁸, Yanqing Hu⁹, Wolfram Brugger¹⁰, Silvia Basilico¹¹, Davide Germano¹¹ and Claire Roddie¹, ¹University College London and University College London Hospital, London, United Kingdom, ²University College London, University College London Hospital and Royal Free Hospital NHS Trust, London, United Kingdom, ³NIHR Manchester CRF, Manchester Royal Infirmary, Manchester, United Kingdom, ⁴Manchester Royal Infirmary, Manchester, United Kingdom, ⁵University of Cambridge, Cambridge, United Kingdom, ⁶Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom, ⁷Hospital Universitari Vall d’Hebron-Universitat Autónoma de Barcelona, Barcelona, Spain, ⁸Hospital Universitari i Politècnic La Fe, Valencia, Spain, ⁹Autolus Therapeutics, Rockville, MD, ¹⁰Autolus Therapeutics, Munich, Germany, ¹¹Autolus Therapeutics, Basel, Switzerland
Background/Purpose: Pts with srSLE have limited remaining treatment options and represent a population with an unmet need. CD19 CAR Ts have potential for deep depletion…
Abstract Number: 1851 • ACR Convergence 2025
Endotype Discovery in Systemic Lupus Erythematosus Using Multi-Omic Approaches: Toward Precision Insights into Cardiovascular and Renal Damage
Chary López pedrera¹, Laurel Woodridge², Sagrario Corrales³, Juan Rafael Muñoz-Castañeda⁴, Ana Isabel Torralbo⁴, Anisur Rahman⁵, Filipa Farinha², Rafaela Ortega-Castro⁶, Pedro Seguí-Azpilcueta⁷, Ismael Sanchez-Pareja³, Laura muñoz-Barrera³, Christian Merlo-Ruiz⁸, Desiree Ruiz-Vilchez⁹, M Carmen Abalos-Aguilera⁸, Pilar Font¹⁰, Nuria Barbarroja¹¹, Marta Alarcon-Riquelme¹², Alejandro Escudero Contreras¹³, MARIA ANGELES AGUIRRE ZAMORANO³, Carlos Pérez Sánchez¹⁴, Elizabeth C Jury⁵ and Tomás Cerdó³, ¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ²Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁴IMIBIC/Hospital Reina Sofía/University of Córdoba, Córdoba, Spain, ⁵University College London, London, United Kingdom, ⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ⁷Radiology Service, Reina Sofia Hospital/Maimonides Institute for Research in Biomedicine of Cordoba/University of Cordoba, Spain, Córdoba, United Kingdom, ⁸Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁹Department of Rheumatology, Reina Sofía University Hospital / Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, ¹⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, SpainBiomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ¹¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹²Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ¹³IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ¹⁴Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disorder characterized by marked clinical variability, which complicates both diagnosis and treatment. Among its most severe…
Abstract Number: 1530 • ACR Convergence 2025
The Renal Activity Index for Lupus Identifies and Predicts Complete Renal Remission or Absence of Kidney Involvement in Systemic Lupus Erythematosus
Guillermo Pons-Estel¹, Rosana Quintana¹, Romina Nieto¹, Hermine Brunner², Marina Scolnik³, Carmen Funes Soaje⁴, Paula Alba⁵, Veronica Saurit⁶, Mercedes Garcia⁷, GUILLERMO ARIEL BERBOTTO⁸, Inés Verónica Bellomio⁹, Mario Eduardo Kerzberg¹⁰, Graciela Gomez¹¹, Cecilia Pisoni¹², Vicente Juarez¹³, Ana Malvar¹⁴, Nélzio Silva¹⁵, ODIRLEI MONTICIELO¹⁶, Henrique Mariz¹⁷, Francinne Ribeiro¹⁸, Eduardo Borba¹⁹, Eloisa Bonfa¹⁹, Edgard Torres dos Reis-Neto²⁰, Iris Guerra Herrera²¹, Maria Loreto Massardo²², Gustavo Aroca-Martínez²³, Lorena Gómez Escorcia²⁴, Carlos Alberto Cañas²⁵, Gerardo Quintana-Lopez²⁶, Carlos Toro-Gutierrez²⁷, Mario Moreno Alvarez²⁸, MIGUEL SAAVEDRA²⁹, Margarita Portela Hernández³⁰, Hilda Fragoso-Loyo³¹, Luis H Silveira³², Ignacio García-De la Torre³³, Carlos Abud-Mendoza³⁴, Jorge Antonio Esquivel Valerio³⁵, Maria Isabel Acosta³⁶, Astrid Paats³⁷, Claudia S. Mora-Trujillo³⁸, Manuel Ugarte-Gil³⁹, Armando Calvo⁴⁰, Roberto Muñoz-Louis⁴¹, Martin Rebella⁴², Alvaro Danza⁴³, Federico Zazzetti⁴⁴, Ashley Orillion⁴⁵, Urbano Sbarigia⁴⁶ and Bernardo A. Pons-Estel⁴⁷, ¹Centro Regional de Enfermedades Autoinmunes y Reumáticas, GO-CREAR, Rosario, Argentina, Rosario, Argentina, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Argentina, ⁴Hospital Italiano de Córdoba, Córdoba, Argentina, Cordoba, Argentina, ⁵Hospital Córdoba y Sanatorio Allende, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina, Cordoba, Argentina, ⁶Hospital Privado Universitario de Cordoba, Córdoba, Argentina, Córdoba, Argentina, ⁷Hospital Interzonal General de Agudos “General San Martín” de la plata, La Plata, Argentina, ⁸Sanatorio Británico, Rosario, Argentina, ROSARIO, Argentina, ⁹Hospital Padilla, Tucumán, Argentina, San Miguel de Tucumán, Argentina, ¹⁰Hospital J.M Ramos Mejía, Buenos Aires, Argentina, CABA, Argentina, ¹¹Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, Buenos Aires, Argentina, Buenos Aires, Argentina, ¹²CEMIC Centro de Educación Médica e Investigaciones Clínicas ‘‘Norberto Quirno”, Buenos Aires, Argentina, Ciudad Autonoma Buenos Aires, Argentina, ¹³Hospital Señor del Milagro Salta, Salta, Argentina, Salta, Argentina, ¹⁴Organización Médica de Investigación, Buenos Aires, Argentina, ¹⁵Hospital das Clinicas da Universidade Federal de Goias, Goias, Brazil, Goiânia, Brazil, ¹⁶Hospital de Clínicas de Porto Alegre, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil, PORTO ALEGRE, Rio Grande do Sul, Brazil, ¹⁷Universidad Federal de Pernambuco, Pernambuco, Brazil, Pernambuco, Brazil, ¹⁸Hospital Universitário Pedro Ernesto - Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, Rio De Janeiro, Rio de Janeiro, Brazil, ¹⁹Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ²⁰Universidad Federal São Paulo, São Paulo, Brazil, São Paulo, Brazil, ²¹Hospital del Salvador Santiago de Chile, Santiago, Chile, Santiago, Chile, ²²Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago, Chile, Santiago, Chile, ²³Clínica de la Costa y Universidad Simón Bolívar, Barranquilla, Colombia, barranquilla, Colombia, ²⁴Clínica de la Costa y Universidad Simón Bolívar Barranquilla, Barranquilla, Colombia, Barranquilla, Colombia, ²⁵Fundación Valle del Lili, Universidad Icesi, Cali, Colombia, Cali, Colombia, ²⁶Facultad de Medicina, Universidad Nacional de Colombia; Hospital Universitario Fundación Santa Fe de Bogotá; Hospital Universitario Nacional de Colombia, Bogotá, Colombia, Bogotá, Colombia, ²⁷Pontificia Universidad Javeriana de Cali, Cali, Colombia, Cali, Colombia, ²⁸Universidad de Especialidades Espíritu Santo, Guayaquil, Ecuador, Guayaquil, Ecuador, ²⁹Hospital de Especialidades Dr. Antonio Fraga Mouret, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mexico, MEXICO, Mexico, ³⁰Hospital de Especialidades del Centro Médico Nacional SXXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico, Mexico City, Mexico, ³¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, ³²Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico City, Mexico, ³³Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Mexico, Guadalajara, Jalisco, Mexico, ³⁴Facultad de Medicina de la Universidad Autónoma de San Luis Potosí y Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, Mexico, San Luis Potosí, Mexico, ³⁵Universidad Autónoma de Nuevo León, Rheumatology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo León, México., MONTERREY, Mexico, ³⁶Facultad de Ciencias Medicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay, Asuncion, Paraguay, ³⁷Facultad de Ciencias Medicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay, Asunción, Paraguay, ³⁸Hospital Nacional Edgardo Rebagliati Martins-EsSalud, Lima, Peru, Lima, Peru, ³⁹Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, ⁴⁰Hospital Nacional Cayetano Heredia Universidad Peruana Cayetano Heredia, Lima, Peru, Jesús María, Peru, ⁴¹Hospital Docente Padre Billini, Santo Domingo, Distrito Nacional, Dominican Republic, ⁴²Hospital de Clínicas, Facultad de Medicina, UDELAR, Montevideo, Uruguay, Montevideo, Uruguay, ⁴³Médica Uruguaya, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay, Montevideo, Uruguay, ⁴⁴Johnson & Johnson, Horsham, PA, USA, Ambler, PA, ⁴⁵Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ⁴⁶Johnson & Johnson, Beerse, Belgium, ⁴⁷Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina
Background/Purpose: Effective, non-invasive disease activity and treatment response assessments are needed for patients with systemic lupus erythematosus (SLE), especially if associated with kidney disease, i.e.…
Abstract Number: 1273 • ACR Convergence 2025
Effectiveness of IV Cyclophosphamide and Mycophenolate Mofetil in the Treatment of Pediatric Systemic Lupus Erythematosus with Lupus Nephritis
adrienne katrin guiang-valerio, University of Santo Tomas Hospital, Mandaluyong, National Capital Region, Philippines
Background/Purpose: Lupus nephritis (LN) is more common in children (occurs in 50-82%) compared to adults. Cyclophosphamide (CYC) and mycophenolate mofetil (MMF) are both treatment options…
Abstract Number: 0655 • ACR Convergence 2025
Blood pressure remains elevated in patients initiating voclosporin with low baseline blood pressure: evidence from patients in routine clinical care
Eric Roberts¹, gabriela Schmajuk² and Jinoos Yazdany³, ¹University of California, San Francisco, SF, CA, ²University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ³UCSF, San Francisco, CA
Background/Purpose: Hypertension was a common adverse event in RCTs testing voclosporin, an oral calcineurin inhibitor approved in 2021 to treat lupus nephritis (LN). In these…
Abstract Number: 0851 • ACR Convergence 2025
Urinary Tenascin C Predicts Kidney Function Loss in Lupus Nephritis
CHEN-YU LEE¹, Sepehr Taghavi², Shangzhu Zhang³, Roopa Madhu⁴, Jasmine Shwetar⁵, Tyler O'Malley⁶, Daniel Goldman⁷, Peter Izmirly⁸, H Michael Belmont⁹, Richard Furie¹⁰, Noa Schwartz¹¹, Chaim Putterman¹², Jennifer Barnas¹³, Jennifer Anolik¹⁴, Sarah French¹⁵, Maria Dall'Era¹⁶, Judith James¹⁷, Joel Guthridge¹⁷, Jacob Vasquez¹⁸, Mike Nerenberg¹⁹, Andrew Concoff²⁰, Christine Schleif²¹, Kevin Wei²², Thomas Eisenhaure²³, Nir Hacohen²³, Rachael Bogle²⁴, Johann Gudjonsson²⁵, Lam Tsoi²⁵, Brad Rovin²⁶, Jill Buyon²⁷, Michelle Petri⁷ and Andrea Fava¹, ¹Johns Hopkins University, Baltimore, MD, ²Exagen Inc, Escondido, CA, ³Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China (People's Republic), ⁴Brigham and Women's Hospital, Brookline, MA, ⁵New York School of Medicine, Ann Arbor, MI, ⁶Exagen, Vista, CA, ⁷Johns Hopkins University School of Medicine, Timonium, MD, ⁸New York University Grossman School of Medicine, New York, NY, ⁹NYU School of Medicine, New York, NY, ¹⁰Division of Rheumatology, Northwell Health, Great Neck, NY, ¹¹Division of Rheumatology, Department of Medicine, Montefiore Medical Center, New York, NY, ¹²Albert Einstein College of Medicine, Safed, Israel, ¹³University of Rochester, Rochester, NY, ¹⁴University of Rochester Medical Center, Rochester, NY, ¹⁵UCSF, Mill Valley, CA, ¹⁶Division of Rheumatology, University of California, San Francisco, CA, ¹⁷Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁸Exagen, Inc., Vista, CA, ¹⁹Exagen, DEL MAR, CA, ²⁰Specialty Networks/United Rheumatology, a Cardinal Health Company, N/A, ²¹Exagen, Carlsbad, CA, ²²Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ²³Broad Institute, Cambridge, MA, ²⁴University of Michigan, Holland, OH, ²⁵University of Michigan, Ann Arbor, MI, ²⁶The Ohio State University, Columbus, OH, ²⁷NYU Grossman School of Medicine, New York, NY
Background/Purpose: Kidney survival is the ultimate treatment goal in lupus nephritis (LN), but long-term predictors remain understudied due to the need for extensive follow up.…

« Previous Page
1
…
5
6
7
8
9
…
44
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].